Samsung Biologics to Join 2026 J.P. Morgan Healthcare Conference

John Rim, President and CEO of Samsung Biologics, delivers a presentation at last years J.P. Morgan Healthcare Conference. (Photo courtesy of Samsung Biologics)

[Song Young Doo, Edaily Reporter] Samsung Biologics said on Jan. 4 it will participate in the 2026 J.P. Morgan Healthcare Conference(JPMHC), the world‘s largest investment event for the pharmaceutical and biotechnology industries.

Now in its 44th year, JPMHC is held every January in San Francisco, California, bringing together leading players from the global pharma, biotech and healthcare sectors. This year’s conference will run from Jan. 12 to 15(local time) and is expected to draw about 1,500 companies and more than 8,000 participants.

Samsung Biologics has been officially invited to the conference for the 10th consecutive year since 2017. The company will deliver its corporate presentation at 3 p.m. on Jan. 13 at the Grand Ballroom of The Westin St. Francis, the conference‘s main venue. Only about 500 industry-leading companies are granted official presentation slots, and the Grand Ballroom is reserved for just 25 select companies, making it one of the most prominent stages at the event.

Presentation order is determined by industry significance. Samsung Biologics is scheduled to present on the second day of the conference alongside major global pharmaceutical companies such as GlaxoSmithKline(GSK), AstraZeneca(AZ) and Eli Lilly.

The presentation will be delivered by CEO John Rim. Titled “ExellenS,” the session is named after the company’s newly launched contract manufacturing organization(CMO) brand and reflects its core value of “4E(Excellence).” Rim will outline Samsung Biologics‘ key achievements over the past year, business plans for 2026, mid- to long-term vision, and the company’s core competitive strengths underpinning its solid growth trajectory.

As a top-tier global contract development and manufacturing organization(CDMO), Samsung Biologics is accelerating its three-pronged expansion strategy focused on production capacity, business portfolio and geographic footprint. The company has been strengthening its future growth engines through initiatives such as its spin-off from Samsung Epis Holdings to become a pure-play CDMO and the acquisition of a manufacturing facility in Rockville, Maryland. Backed by these efforts, Samsung Biologics surpassed $20 billion in cumulative orders last year, posting steady performance growth.

During the conference, Samsung Biologics plans to hold extensive meetings with global investors and potential clients to showcase its differentiated CDMO capabilities and further expand its global business network.